(VIANEWS) – Shares of Moderna (NASDAQ: MRNA) rose 9.1% to $138.27 at 12:24 EST on Tuesday, after two sequential sessions in a row of gains. NASDAQ is dropping 0.14% to $12,703.32, following the last session’s upward trend. This seems, up until now, a somewhat down trend exchanging session today.
Moderna’s last close was $126.74, 41.66% under its 52-week high of $217.25.
About Moderna
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Earnings Per Share
As for profitability, Moderna has a trailing twelve months EPS of $11.31.
PE Ratio
Moderna has a trailing twelve months price to earnings ratio of 12.23. Meaning, the purchaser of the share is investing $12.23 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.62%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 69.3%, now sitting on 15.06B for the twelve trailing months.
More news about Moderna (MRNA).
